The protein was originally isolated by Kato and coworkers from human squamous cell carcinoma tissue and shown to consist of at least 10 subfractions differing in isoelectric point. More recent studies have shown that SCC antigen is composed of two distinct but highly homologous gene products, SCCA1 and SCCA2 with different inhibitor specificities.
SCC antigen is a serological marker of squamous cell carcinomas of the uterine cervix, lung, head & neck, vulva and esophagus. In squamous cell carcinoma of the uterine cervix, pre-treatment serum SCC ag may be used as an early stage prognostic factor and the use of pre-treatment SCC ag has been suggested in order to select high-risk patients for adjuvant therapy. Further, for patients with elevated levels of SCC ag before start of treatment, the profile of SCC ag correlates with the response to radio- and chemotherapy and measurement of SCC ag may thus be used for early detection of recurrent disease and to monitor the effect of therapy.
For more information, visit Fujirebio.com.